Diabetes Mellitus, Type 2
Conditions
Brief summary
The purpose of this study is to estimate the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and short-acting human insulin therapy within the first year following the switch. The additional goals are: 1)to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient treatment satisfaction, 2) to assess the impact of a switch from or to a rapid-acting analog insulin therapy on patient quality of life, 3) to assess the impact of switch from or to the rapid-acting analog insulin therapy on the quality of metabolic control and, 4) to estimate the total costs (direct and indirect) associated with switching, in either direction between rapid-acting analog and short-acting human insulin within the first year following the switch.
Interventions
DRUGAnalog or Human Insulin
prescribed in accordance with usual clinical practice
Sponsors
Eli Lilly and Company
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* are at least 18 years of age * according to the clinical judgement of the investigator have been diagnosed with type II diabetes * have presented within the normal course of care * at the baseline visit are being treated with any therapy including a rapid-acting analog insulin component or any therapy including a short-acting human insulin component and are switching from one form of therapy to the other * are not simultaneously participating in a study that includes an investigational drug or procedure at entry into the study * have been fully informed and have given their written consent for the use of their data * have a sufficient understanding of the primary language of the country such that they will be able to complete the questionnaires
Exclusion criteria
* no specific
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The estimation of the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and a short-acting human insulin therapy within the first year following the switch. | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Change in Euro Quality of Life (EQ-5D) | 1 year |
| Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) | 1 year |
| Change in Diabetes Health Profile (DHP-18) | 1 year |
| The estimation of the total costs (direct and indirect) associated with switching, in either direction, between rapid-acting analog and short-acting human insulin within the first year following the switch | 1 year |
Countries
Austria, Czechia, Germany, Greece, Hungary, Poland, Romania, Slovakia, Turkey (Türkiye)
Outcome results
None listed